TSCAN THERAPEUTICS INC

TCRXNASDAQ

🏆 #4746 by market capUS Equity

$0.32▼ $0.02 (−6.51%)

After hours · at close

🔔

Track TCRX

Get earnings, price moves & breaking news on Telegram

Track

24h▼ 6.5%

7d▼ 9.0%

14d▲ 0.1%

30d▼ 57.5%

ytd▼ 67.9%

1y▼ 81.4%

🏦Market Cap

$21M

Small Cap

📈Revenue Growth (YoY)

+2.1%

Slowing

📊Gross Margin

—

💵FCF Margin

—

⚖️P/S Ratio

3.2x

Fair

Otter Score

Fair

Trading Snapshot

Day Range: $0.31 – $0.32
52-Week Range: $0.29 – $2.57
Volume: $3.25B
Avg Volume: $3.73B
Shares Outstanding: 65.3M
Next Earnings: Oct 17, 2026

Fundamentals Snapshot

Annual Revenue: $10M
Last Q Revenue: $1M
P/E Ratio: —
P/S Ratio: 3.2x
EPS (TTM): $-0.91
Dividend Yield: —
Dilution (1yr): +7.5%

Why Investors Own TCRX

✓High-growth profile — revenue up +17.7% YoY with expanding US Equity exposure.
✓Healthy economics — 40% gross margin and 14% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

TSCAN THERAPEUTICS INC

TCRX

Financial Trends

Revenue

$10M▲ +266.7% YoY

Gross Margin

72.2%▼ −27.8% YoY

Operating Income

−$136M▲ +0.7% YoY

Free Cash Flow

−$140M▲ +21.9% YoY

Shares Outstanding

129.9M▲ +7.5% YoY

Net Cash

$58M▼ −$23M YoY

StockOtter · stockotter.space

About TSCAN THERAPEUTICS INC

TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company’s lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT), which is in Phase I clinical trial, as well as eliminates residual disease and promotes donor chimerism. It also develops TSC-102-A01 and TSC-102-A03, which are allogeneic and donor-derived TCR-T therapy candidates targeting epitopes. In addition, the company develops TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. It has a research collaboration and license agreement with Amgen Inc. to identify antigens recognized by T cells in patients with Crohn’s disease. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

🦦